APD Gains on Growth Project and Productivity Amid Helium Pricing Woes

Air Products raised fiscal 2026 adjusted EPS guidance to $13.39-$13.49 from $13.00-$13.25, supported by a roughly $3 billion industrial-gas project backlog, electronics demand and productivity measures. The company expects $250 million of annual savings from headcount reductions, of which roughly $75 million has already been realized, while investing about $1.5 billion annually in traditional industrial-gas projects. Its NEOM project is expected to produce up to 1.2 million tons annually of renewable ammonia, with Yara contracted to distribute volumes not sold by APD as hydrogen. Lower helium pricing remains a material offset, projected to reduce earnings by roughly 2% in fiscal Q4 and 3% in fiscal 2026.

Analysis

APD’s near-term earnings upgrade is less important than the quality of its offset: labor savings are controllable, while helium pricing is not. The key underwriting question over the next 1-3 months is whether management can convert announced restructuring into run-rate savings without service disruption or project-delay costs; if so, incremental EBITDA conversion should be superior to commodity-chemical peers whose self-help programs remain more exposed to weak end-market volumes. Electronics-linked onsite projects also give APD a cleaner semiconductor-capex sensitivity than DOW, EMN, or CE.

The renewable-ammonia agreement reduces commercialization risk for NEOM but does not eliminate the more consequential risks: construction execution, Saudi-country concentration, power/feedstock economics, and the willingness of end customers to pay a durable green premium. Yara’s involvement is strategically favorable for distribution, but it may cap APD’s upside participation on volumes it does not market directly. The 6-18 month catalyst is evidence of contracted offtake, commissioning milestones, and project-finance discipline—not additional partnership announcements.

A non-obvious read-through is that helium deflation can be a modest customer-margin tailwind for helium-intensive healthcare, semiconductor and analytical-instrument users, while it pressures APD’s mix. This makes APD’s valuation rerating dependent on showing that electronics volume and productivity outweigh a price headwind, rather than simply on a broad chemicals recovery. Consensus may be underestimating APD’s resilience versus commodity chemicals, but overestimating the speed at which a large clean-hydrogen project becomes cash-generative.

DOW, EMN and CE should not be treated as direct substitutes for APD: their cost programs can protect downside but do not provide the same contracted-project duration. In a soft industrial-demand scenario, APD/DOW relative performance should widen; in a sharp China-led manufacturing rebound, lower-quality cyclicals CE and DOW offer more operating leverage and can outperform despite weaker structural visibility.

Key Decisions for Investors

• Initiate a 3-6 month long APD / short DOW pair, dollar-neutral, on the view that APD’s contracted electronics exposure and self-help are more defensible than DOW’s commodity-volume recovery. Target 8-12% relative return; exit if APD lowers FY2026 EPS guidance or DOW’s volume/pricing outlook improves materially for two consecutive reporting periods.
• Keep CE as a tactical, not structural, long: only add following evidence of improving acetyl-chain pricing or a China-demand inflection. Its earnings and free-cash-flow delivery are more sensitive to cyclical utilization than APD; use a 3-month horizon with a 10% downside stop rather than underwriting a multiple rerating today.
• Watch APD’s next earnings release for three datapoints before increasing gross exposure: realized restructuring savings versus the annual target, helium-price impact versus guidance, and electronics-project backlog conversion. Failure on any two is thesis-invalidating and warrants reducing APD relative longs.
• Do not underwrite YAR as a standalone green-ammonia trade solely from the distribution arrangement. Reassess over 6-12 months only if disclosed contracted volumes, pricing structure, and capital commitments demonstrate returns above Yara’s conventional fertilizer-cycle alternatives.